Trevor Burt, MD

Neonatologist

Dr. Trevor D. Burt is a neonatologist, specializing in the care of critically ill newborns, including premature infants and newborns requiring intensive care such as those with birth and cardiac defects, surgical issues and genetic syndromes. He also treats babies who have difficulty or trauma before or during birth and those who require extracorporeal membranous oxygenation (ECMO) for cardiac and respiratory support.

In his research, he focuses on the immune system and its role in HIV and other chronic infections, as well as the development of immune systems and how they influence response to infection. Burt earned a medical degree at Harvard Medical School. He completed a combined internship and residency in pediatrics at Children's Hospital Boston and Boston Medical Center and a fellowship in neonatal-perinatal medicine at UCSF. He is a fellow of the American Academy of Pediatrics and a member of the California Thoracic Society. At UCSF, he is an assistant adjunct professor of pediatrics in the School of Medicine.

Clinics

Fetal Treatment Center
1855 Fourth St., Second Floor, Room A-2432
San Francisco, CA 94158
Phone: (800) 793-3887
Fax: (415) 502-0660

Hours: Monday to Friday
8 a.m. - 5 p.m.

Academic Title

Assistant Professor

More about Trevor Burt

Additional Languages

French

Education

Harvard School of Medicine 2002

Residencies

Children's Hospital of Boston, Pediatrics 2005

Fellowships

UCSF Medical Center, Neonatology 2009

Selected Research and Publications

  1. Kattah MG, Milush JM, Burt T, McCabe RP, Whang MI, Ma A, Mahadevan U. Anti-TNF and thiopurine therapy in pregnant IBD patients does not significantly alter a panel of B-cell and T-cell subsets in 1-year-old infants. Clin Transl Gastroenterol. 2018 Apr 03; 9(4):143.
  2. Bronevetsky Y, Burt TD, McCune JM. Lin28b Regulates Fetal Regulatory T Cell Differentiation through Modulation of TGF- Signaling. J Immunol. 2016 12 01; 197(11):4344-4350.
  3. Seu L, Ortiz GM, Burt TD, Deeks SG, Martin JN, McCune JM. Levels of circulating myeloid subpopulations and of heme oxygenase-1 do not predict CD4(+) T cell recovery after the initiation of antiretroviral therapy for HIV disease. AIDS Res Ther. 2014; 11:27.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.